Pharmaron Beijing Co., Ltd. (300759.SZ)
- Previous Close
22.67 - Open
23.04 - Bid 23.22 x --
- Ask 23.23 x --
- Day's Range
22.71 - 23.71 - 52 Week Range
17.70 - 36.42 - Volume
36,999,902 - Avg. Volume
23,654,277 - Market Cap (intraday)
38.147B - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
22.10 - EPS (TTM)
1.05 - Earnings Date Apr 25, 2025
- Forward Dividend & Yield 0.20 (0.86%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
29.91
Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
www.pharmaron.comRecent News: 300759.SZ
View MorePerformance Overview: 300759.SZ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300759.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300759.SZ
View MoreValuation Measures
Market Cap
38.15B
Enterprise Value
41.43B
Trailing P/E
22.00
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.23
Price/Book (mrq)
2.94
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
17.24
Financial Highlights
Profitability and Income Statement
Profit Margin
14.71%
Return on Assets (ttm)
4.65%
Return on Equity (ttm)
12.70%
Revenue (ttm)
12.7B
Net Income Avi to Common (ttm)
1.87B
Diluted EPS (ttm)
1.05
Balance Sheet and Cash Flow
Total Cash (mrq)
2.69B
Total Debt/Equity (mrq)
40.69%
Levered Free Cash Flow (ttm)
-339.13M